BridgeMD
Stopping or continuing blood thinners after stroke at young age without a known cause: STOP trial
EU CTIS ID: 2024-513092-40-00
What this study is testing
To investigate whether discontinuation of antiplatelet therapy is non-inferior to continuation of antiplatelet therapy, to prevent major cardiovascular events three to ten years after cryptogenic TIA or ischaemic stroke at young age.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- First ever ischaemic stroke, or TIA with evidence of ischaemia on imaging, 3-10 years prior to study participation
- Age 18-49 years at the time of TIA/ischaemic stroke
- Cryptogenic aetiology, defined as no other aetiology after standard work-up according to national and international guidelines for young stroke (imaging of the brain (CT-scan or MRI-scan) and cervical arteries (CTA, MRA or carotid ultrasound), routine blood tests (complete blood count, erythrocyte sedimentation rate, CRP, antiphospholipid antibodies), ECG, at least 24 hours cardiac rhythm monitoring and transthoracic/transesophageal echocardiography).
You likely can't join if
- History of MI, coronary revascularisation or documented peripheral arterial disease
- Other indication for antiplatelet therapy
- Indication for oral anticoagulants or low molecular weight heparin
- Recurrent ischaemic event at any time after the index event
- Any stenosis of intracranial or cervical artery at time of stroke
- Two or more risk factors for atherosclerotic disease according to the following definitions: • arterial hypertension (treated or known blood pressure before stroke >140/90 mm Hg) • diabetes mellitus (treated or known blood fasting glucose >7 mmol/l) • current smoking (or smoking stopped within the last 6 months), • hypercholesterolaemia (treated or known low-density lipoprotein before the stroke >160 mg/dl or 4, mmol/l)
See the full eligibility criteria
- First ever ischaemic stroke, or TIA with evidence of ischaemia on imaging, 3-10 years prior to study participation
- Age 18-49 years at the time of TIA/ischaemic stroke
- Cryptogenic aetiology, defined as no other aetiology after standard work-up according to national and international guidelines for young stroke (imaging of the brain (CT-scan or MRI-scan) and cervical arteries (CTA, MRA or carotid ultrasound), routine blood tests (complete blood count, erythrocyte sedimentation rate, CRP, antiphospholipid antibodies), ECG, at least 24 hours cardiac rhythm monitoring and transthoracic/transesophageal echocardiography).
- History of MI, coronary revascularisation or documented peripheral arterial disease
- Other indication for antiplatelet therapy
- Indication for oral anticoagulants or low molecular weight heparin
- Recurrent ischaemic event at any time after the index event
- Any stenosis of intracranial or cervical artery at time of stroke
- Two or more risk factors for atherosclerotic disease according to the following definitions: • arterial hypertension (treated or known blood pressure before stroke >140/90 mm Hg) • diabetes mellitus (treated or known blood fasting glucose >7 mmol/l) • current smoking (or smoking stopped within the last 6 months), • hypercholesterolaemia (treated or known low-density lipoprotein before the stroke >160 mg/dl or 4, mmol/l)
- Any condition that prevents long-term follow-up
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.